Orthobond Unveils Anti-Microbial Surface Technology Designed to Destroy Pathogens on Contact at The American Academy of Orthopaedic Surgeons Annual Meeting

press-release-strep-bacteria-compete-for-ownership-of-human-tissue

The patented, non-eluting and non-antibiotic surface treatment from Orthobond is designed to eliminate microbes on metallic and polymeric surfaces

PRINCETON, N.J., August 25, 2021–(BUSINESS WIRE)–Orthobond today announced its patented antimicrobial nanosurface technology will be unveiled at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego, September 1 through 3. Orthobond’s surface technology is the only non-eluting and non-antibiotic treatment designed for medical implants. The company is completing safety and efficacy testing for FDA marketing submission in late 2021.*

Contamination has a serious impact on patient care, and Orthobond’s technology has the potential to improve outcomes with medical devices, such as implants and instruments in orthopedics, plastic surgery, cardiovascular and other implantable device areas. Orthobond’s antimicrobial nanosurface treatment is designed to kill viruses, bacteria and fungi by rupturing the pathogen.

“The world is focused on pathogens more than ever, and we understand the need for protection,” said David Nichols, CEO of Orthobond. “Orthobond’s technology creates a covalently bound nanosurface that is designed to kill bacteria, viruses and fungi, yet is safe for human contact. Our first products will be a series of antimicrobial medical device surface treatments designed to protect from pathogens without the use of drugs or eluting chemicals, but long term we see broad applications for textiles, consumer goods and high-touch areas in public places.”

The Orthobond team has worked for over a decade to improve patient outcomes by developing technologies that aim to kill pathogens. In the process, Orthobond has tested over a thousand different linker-agent combinations to create the best solution, unlike anything that is currently on the market. Orthobond’s technology makes use of powerful covalent linker technology that presents a highly efficacious antimicrobial with broad-spectrum activity directly on the device surface.

The Orthobond team will be at AAOS at the San Diego Convention Center in booth number 4050. For all business inquiries, email Chuck Reynolds, reynoldsc@orthobond.com; for press interested in meeting at AAOS or for further info, email Amber Stafford, amber@neilsonswiader.com.

To learn more about Orthobond visit orthobond.com or Orthobond’s LinkedIn page.

About Orthobond

Orthobond is an antimicrobial technology company that has developed proprietary antimicrobial nanosurfaces, with broad applications in the medical device industry and more such as commercial, industrial, automotive, and beyond. We’re the first company to utilize nanoscale surface modifications that can be permanently bound to any surface, killing bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics.

* Regulatory Disclaimer: Supporting data on file at Orthobond. The subject devices are not FDA cleared or approved and pending marketing submission Q4 2021.

Contacts: